1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
- Hamlet Hayrapetyan, MD, PhD, - Double – Blind , Randomized, Parallel, Placebo Controlled Study Examining the Effect of Cross- Linked Polyelectrolyte (CLP) in Heart Failure Patients with Chronic Kidney Disease
- Hamlet Hayrapetyan, MD, PhD, - Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomized double – blind Placebo- controlled international multicenter study. Study assessing the morbi - mortality benefits of the If inhibitor Ivad
- Hamlet Hayrapetyan, MD, PhD, - Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris. A 6-week randomised do
- - Iodine deficiency, hypothyroidism and infertility
- - New directions used in the practice of the treatment of heart failure – Coraxan
- Haroutyun Mangoyan MD, Ph.D., - Prospective evaluation of non-invasive ICP monitoring in patients undergoing invasive ICP monitoring
- Armine Kteyan MD, Tatyana Stepanyan, MD, - QUTENZATM versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, non-inferiority efficacy and tolerability study
- - Safety and efficacy of fixed dose combination of indapamide SR/Amlodipine in single- pill versus free dual therapy at the same dose over 12 – week of treatment, with conditional titration based on the blood pressure control, in patients with mild to moder
